Based on blinded independent central review (BICR), the objective response rate (ORR) with dato-DXd was 25.0% (n = 10/40; 95% CI, 12.7%-41.2%), which included 1 ...

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...

If you are worried about using this medicine, speak to your doctor or pharmacist. 1. Why am I using Herceptin SC? Herceptin SC contains the active ingredient trastuzumab. Herceptin SC is used to ...

This study presents a useful finding that targeting amino acid metabolism can overcome Trastuzumab resistance in HER2+ breast cancer. The evidence supporting the claims of the authors is solid and the ...

This enables the identification of patients with hormone receptor (HR)-positive, HER2-ultralow metastatic breast cancer who may be eligible for fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) ...

This crisis has been worsened by the transition from the NHIF to the Social Health Authority (SHA), which has caused widespread disruptions in healthcare services. Be part of an exclusive group of ...

MONDAY, Feb. 3, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with unresectable or metastatic hormone ...

Enhertu (fam-trastuzumab deruxtecan-nxki) Therapy in HER2-Low and -Ultralow Breast Cancer It was announced on Jan. 27 that the antibody drug conjugate Enhertu was granted FDA approval for the ...

The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, human ...

T-DXd for HER2-Low and -Ultralow Metastatic Breast Cancer The FDA has approved fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for unresectable or metastatic, HR-positive breast cancer with HER2-low ...

The government had earlier cut customs duties on Trastuzumab Deruxtecan, Osimertinib and Durvalumab from 10 per cent to nil. "To provide relief to patients, particularly those suffering from ...